Jefferies Group Analysts Lower Earnings Estimates for Hikma Pharmaceuticals Plc (HKMPF)

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) – Equities researchers at Jefferies Group dropped their FY2017 EPS estimates for shares of Hikma Pharmaceuticals in a note issued to investors on Monday. Jefferies Group analyst J. Vane-Tempest now expects that the company will post earnings of $0.88 per share for the year, down from their previous forecast of $0.92. Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for Hikma Pharmaceuticals’ FY2018 earnings at $0.81 EPS, FY2019 earnings at $0.85 EPS, FY2020 earnings at $0.96 EPS and FY2021 earnings at $1.03 EPS.

HKMPF has been the subject of a number of other research reports. Zacks Investment Research cut Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. Goldman Sachs Group lowered Hikma Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 22nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold”.

Shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) opened at $13.60 on Tuesday. Hikma Pharmaceuticals has a 1-year low of $12.40 and a 1-year high of $27.50.

ILLEGAL ACTIVITY WARNING: This report was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply